eHealth company Respiri (ASX:RSH) has received firm commitments for a company-led $1.6 million strategic placement at $0.045 per share.
The company said institutional investor Merchant Biotech Fund and others, including Hamma Capital, have joined its share registry.
Respiri said it is progressing with its US plans to support patient health through connected health management solutions that are proven to reduce healthcare events.
Respiri chairman Nicholas Smedley said, “The Board and I are pleased to welcome investors of this calibre onto our registry. This is a significant endorsement of our US strategy and the executional capabilities of Marjan, our CEO, and the rest of the Respiri team. With this track record and anticipated future achievements, we remain confident of achieving profitability in the imminent future.”
